Products - Ear, nose and throat conditions | Topic

Showing 17 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) (TA972)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 May 2024
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA847)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 November 2022
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 October 2022
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 August 2021
Published:
26 March 2008
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 September 2020
Cochlear implants for children and adults with severe to profound deafness (TA566)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 March 2019
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
12 February 2025
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
12 November 2025
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Benralizumab for previously treated severe nasal polyps [ID1659]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis [ID6480]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years TSID 12054
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Ear, nose and throat conditions Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 17 products

Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) (TA972)

Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA847)

SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)

Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)

Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)

Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)

Cochlear implants for children and adults with severe to profound deafness (TA566)

12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

Benralizumab for previously treated severe nasal polyps [ID1659]

Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918

Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449

Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462

Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis [ID6480]

Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years TSID 12054

Ear, nose and throat conditions Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 17 products

Guidance programme
1 selected